GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Obesity

Volumn 23, Issue 6, 2015, Pages 1119-1129

  Ryan, Donna ^a   Acosta, Andres ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN;

BODY WEIGHT; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLECYSTITIS; CHOLELITHIASIS; DRUG APPROVAL; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART PROTECTION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; OBESITY; PANCREATITIS; PARKINSON DISEASE; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RISK REDUCTION; SALIVA; TASTE; WEIGHT REDUCTION; AGONISTS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; PATHOPHYSIOLOGY;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84929947880     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21107     Document Type: Review

References (125)

1. Drucker DJ,. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
2. Holst JJ, Christensen M, Lund A, et al., Regulation of glucagon secretion by incretins. Diabet Obes Metab 2011; 13 (Suppl 1): 89-94.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al., Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
4. Gerich J,. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med 2013; 6: 877-895.
5. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
6. Committee for Medicinal Products for Human Use (CHMP) EMA. Assessment Report: Eperzan (albiglutide) 23 January 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002735/WC500165119.pdf. Last accessed February 2015.
7. Highlights of Prescribing Information: Trulicity (dulaglutide). Available at: http://pi.lilly.com/us/trulicity-uspi.pdf). Last accessed February 2015.
8. Glaesner W, Vick AM, Millican R, et al., Engineering and characterization of the long-acting glucagon-like peptide-1 analogue ly2189265, an fc fusion protein. Diabet Metabol Res Rev 2010; 26: 287-296.
9. Highlights of Prescribing Information: BYDUREON (exenatide). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022200s000lbl.pdf). Last accessed February 2015.
10. Christensen M, Knop FK,. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide?. Curr Diabet Rep 2010; 10: 124-132.
11. Highlights of US prescribing information Victoza®. Available at: www.novo-pi.com/victoza.pdf. Last accessed February 2015.
12. Meier JJ,. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
13. American Diabetes A. Standards of medical care in diabetes-2015. Diabet Care 2015; 38: S1-S93.
14. Pi-Sunyer X, Blackburn G, Brancati FL, et al., Reduction in weight cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabet Care 2007; 30: 1374-1383.
15. Vilsboll T, Garber AJ., Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabet Obes Metab 2012; 14 (Suppl 2): 41-49.
16. Seufert J, Gallwitz B,. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabet Obes Metab 2014; 16: 673-688.
17. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL,. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (Clin Res Ed) 2012; 344: d7771.
18. Zhang F, Tong Y, Su N, et al., Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. J Diabet, 2014 Jul 15. doi: 10.1111/1753-0407.12198.
19. Holst JJ, Deacon CF,. Is there a place for incretin therapies in obesity and prediabetes?. Trends Endocrinol Metab 2013; 24: 145-152.
20. FDA. FDA approves weight-management drug Saxenda. December 23, 2014.
21. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH,. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes 2014; 38: 784-793.
22. Jendle J, Nauck MA, Matthews DR, et al., Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabet Obes Metab 2009; 11: 1163-1172.
23. Astrup A, Carraro R, Finer N, et al., Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012; 36: 843-854. Erratum in Int J Obes (Lond). 2013 Feb;2037(2012):2322.
24. Astrup A, Rossner S, Van Gaal L, et al., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
25. Wadden TA, Hollander P, Klein S, et al., Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013; 37: 1443-1451.
26. Rosenstock J, Klaff LJ, Schwartz S, et al., Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabet Care 2010; 33: 1173-1175.
27. Kelly AS, Rudser KD, Nathan BM, et al., The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167: 355-360.
28. Dushay J, Gao C, Gopalakrishnan GS, et al., Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabet Care 2012; 35: 4-11.
29. Davies M, Bode BW, Kushner RF, et al., Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: results from the SCALE™ diabetes 56-week randomized, double-blind, placebo-controlled trial (abstract). Am Diabet Assoc 74th Sci Sessions 2014;A26:97-OR.
30. DeFronzo RA, Bergenstal RM, Bode B, et al., Effects of liraglutide 3.0 mg and 1.8 mg on body weight and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes mellitus (T2DM): the SCALE diabetes randomized, double-blind, placebo-controlled, 56-week trial (abstract). 16th International Congress of Endocrinology (ENDO 2014). SAT-0930.
31. Lau DC, Astrup A, Fujioka K, et al., Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial (abstract). 16th International Congress of Endocrinology (ENDO 2014). SAT-0929.
32. Pi-Sunyer FX, Astrup A, Fujioka K, et al., Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight and obese adults: results from SCALE obesity and prediabetes, a randomized, double-blind and placebo-controlled 56-week trial (abstract). 16th International Congress of Endocrinology (ENDO 2014). PP05-4. SAT-0925.
33. Roux CL, Astrup A, Fujioka K, et al., Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial (abstract). 16th International Congress of Endocrinology (ENDO 2014). SAT-0937.
34. Wilding J, Astrup A, Fujioka K, et al., Liraglutide 3.0 mg improves insulin secretion and action in overweight and obese adults without diabetes: results from SCALE obesity and prediabetes, a randomized, double-blind and placebo-controlled 56-week trial (abstract). 16th International Congress of Endocrinology (ENDO 2014). SAT-0931.
35. Ahren B, Johnson SL, Stewart M, et al., HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabet Care 2014; 37: 2141-2148.
36. Raccah D, Gourdy P, Sagnard L, Ceriello A,. Lixisenatide as add-on to oral antidiabetic therapy: an effective treatment for glycemic control with body weight benefits in type 2 diabetes. Diabet Metab Res Rev 2014; 30: 742-748.
37. Umpierrez GE, Blevins T, Rosenstock J, et al., The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabet Obes Metab 2011; 13: 418-425.
38. Pyke C, Heller RS, Kirk RK, et al., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-1290.
39. Herzlinger S, Horton ES,. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabet Res Clin Practice 2013; 100: 1-10.
40. Burgmaier M, Heinrich C, Marx N,. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabet Med J Br Diabet Assoc 2013; 30: 289-299.
41. Xiong H, Zheng C, Wang J, et al., The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J Alzheimer's Dis 2013; 37: 623-635.
42. Yusuf S, Hawken S, Ounpuu S, et al., Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
43. Li G, Zhang P, Wang J, et al., Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the da qing diabetes prevention study: a 23-year follow-up study. Lancet Diabet Endocrinol 2014; 2: 474-480.
44. Wing RR, Bolin P, Brancati FL, et al., Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154.
45. Yanovski SZ, Yanovski JA,. Long-term drug treatment for obesity: a systematic and clinical review. JAMA J Am Med Assoc 2014; 311: 74-86.
46. van Genugten RE, Moller-Goede DL, van Raalte DH, Diamant M,. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabet Obes Metab 2013; 15: 593-606.
47. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E,. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabet Obes Metab 2014; 16: 38-47.
48. Best JH, Hoogwerf BJ, Herman WH, et al., Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabet Care 2011; 34: 90-95.
49. Wang B, Zhong J, Lin H, et al., Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabet Obes Metab 2013; 15: 737-749.
50. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP,. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3: piie001986.
51. Filippatos TD, Elisaf MS,. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabet 2013; 4: 190-201.
52. Nystrom T, Gonon AT, Sjoholm A, Pernow J,. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173-177.
53. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T,. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012; 9: 209-222.
54. Kim M, Platt MJ, Shibasaki T, et al., GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567-575.
55. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS,. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connect 2014; 3: 11-16.
56. Liraglutide 3.0 mg for Weight Management (NDA 206-321). Briefing Document. Endocrinologic and Metabolic Drug Advisory Committee, September 11, 2014 [cited 2014 24 September]. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413318.pdf. Last accessed February 2015.
57. Arakawa M, Mita T, Azuma K, et al., Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
58. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE,. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diabet Vasc Dis Res Off J Int Soc Diabet Vasc Dis 2013; 10: 353-360.
59. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD,. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabet Care 2010; 33: 1028-1030.
60. Nikolaidis LA, Elahi D, Hentosz T, et al., Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-961.
61. Nikolaidis LA, Mankad S, Sokos GG, et al., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-965.
62. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP,. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Failure 2006; 12: 694-699.
63. Noyan-Ashraf MH, Momen MA, Ban K, et al., GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983.
64. Liu Q, Anderson C, Broyde A, et al., Glucagon-like peptide-1 and the exenatide analogue ac3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010; 9: 76.
65. Wohlfart P, Linz W, Hubschle T, et al., Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Trans Med 2013; 11: 84.
66. Lonborg J, Vejlstrup N, Kelbaek H, et al., Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491-1499.
67. Courreges JP, Vilsboll T, Zdravkovic M, et al., Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med J Br Diabet Assoc 2008; 25: 1129-1131.
68. Bunck MC, Diamant M, Eliasson B, et al., Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabet Care 2010; 33: 1734-1737.
69. Tibble CA, Cavaiola TS, Henry RR,. Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Rev Endocrinol Metab 2013; 8: 247-259.
70. Available at: ClinicalTrials.gov
71. Miller AA, Spencer SJ,. Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun 2014; 42: 10-21.
72. de la Monte SM,. Relationships between diabetes and cognitive impairment. Endocrinol Metab Clin North Am 2014; 43: 245-267.
73. Holst JJ, Burcelin R, Nathanson E,. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011; 27: 547-558.
74. Holscher C,. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014; 221: T31-T41.
75. McClean PL, Parthsarathy V, Faivre E, Holscher C,. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci Off J Soc Neurosci 2011; 31: 6587-6594.
76. Hunter K, Holscher C,. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33.
77. Gengler S, McClean PL, McCurtin R, Gault VA, Holscher C,. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/ps1 mice. Neurobiol Aging 2012; 33: 265-276.
78. Li Y, Duffy KB, Ottinger MA, et al., GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimer's Dis 2010; 19: 1205-1219.
79. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al., Exenatide and the treatment of patients with Parkinson's disease. J Clin Investig 2013; 123: 2730-2736.
80. Muskiet MH, Smits MM, Morsink LM, Diamant M,. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10: 88-103.
81. Campos RV, Lee YC, Drucker DJ,. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156-2164.
82. Crajoinas RO, Oricchio FT, Pessoa TD, et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301: F355-F363.
83. Schlatter P, Beglinger C, Drewe J, Gutmann H,. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regulat Pept 2007; 141: 120-128.
84. Pezeshki A, Muench GP, Chelikani PK,. Short communication: expression of peptide YY, proglucagon, neuropeptide Y receptor y2, and glucagon-like peptide-1 receptor in bovine peripheral tissues. J Dairy Sci 2012; 95: 5089-5094.
85. Yu M, Moreno C, Hoagland KM, et al., Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135.
86. Gutzwiller JP, Tschopp S, Bock A, et al., Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-3061.
87. Rieg T, Gerasimova M, Murray F, et al., Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 2012; 303: F963-F971.
88. Skov J,. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord 2014; 15: 197-207.
89. Hall ME, do Carmo JM, da Silva AA, et al., Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014; 7: 75-88.
90. Van Buren PN, Toto R,. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011; 18: 28-41.
91. Hendarto H, Inoguchi T, Maeda Y, et al., GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metab Clin Exp 2012; 61: 1422-1434.
92. Kodera R, Shikata K, Kataoka HU, et al., Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
93. Park CW, Kim HW, Ko SH, et al., Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
94. Mima A, Hiraoka-Yamomoto J, Li Q, et al., Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967-2979.
95. Chaudhuri A, Ghanim H, Vora M, et al., Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012; 97: 198-207.
96. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al., Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Disposit Biol Fate Chem 2010; 38: 1944-1953.
97. Summary of Product Characteristics Victoza®. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf). Last accessed February 2015.
98. Summary of Product Characteristics Eperzan®. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002735/WC500165117.pdf. Last accessed February 2015.
99. Highlights of US prescribing information TANZEUM™. Available at: https://www.gsksource.com/gskprm/htdocs/documents/TANZEUM-PI-MG-IFU-COMBINED.PDF). Last accessed February 2015.
100. Summary of Product Characteristics Lyxumia®. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002445/WC500140401.pdf. Last accessed February 2015.
101. Samson SL, Bajaj M,. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabet Compl 2013; 27: 401-406.
102. Armstrong MJ, Barton D, Gaunt P, et al., Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open 2013; 3: e003995.
103. Eguchi Y, Kitajima Y, Hyogo H, et al., Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res Off J Jpn Soc Hepatol Res, 2015 Mar; 45 (3): 269-78. doi: 10.1111/hepr.12351.
104. Gupta NA, Kolachala VL, Jiang R, et al., The glucagon-like peptide-1 receptor agonist exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol 2012; 181: 1693-1701.
105. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP,. Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
106. Messenger B, Clifford MN, Morgan LM,. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. J Endocrinol 2003; 177: 407-412.
107. Shin YK, Martin B, Golden E, et al., Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 2008; 106: 455-463.
108. Martin B, Dotson CD, Shin YK, et al., Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci 2009; 1170: 98-101.
109. Martin C, Passilly-Degrace P, Chevrot M, et al., Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of gpr120 and impact on taste sensitivity. J Lipid Res 2012; 53: 2256-2265.
110. Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C, Rozengurt E,. Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon. Am J Physiol Gastrointest Liver Physiol 2006; 291: G792-G802.
111. Kokrashvili Z, Mosinger B, Margolskee RF,. Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones. Am J Clin Nutr 2009; 90: 822s-825s.
112. Margolskee RF, Dyer J, Kokrashvili Z, et al., T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007; 104: 15075-15080.
113. Hirasawa A, Tsumaya K, Awaji T, et al., Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through gpr120. Nat Med 2005; 11: 90-94.
114. Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V,. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 2014; 3: 191-201.
115. Acosta A, Abu Dayyeh BK, Port JD, Camilleri M,. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 2014; 63: 687-695.
116. Pepino MY, Bradley D, Eagon JC, Sullivan S, Abumrad NA, Klein S, Changes in taste perception and eating behavior after bariatric surgery-induced weight loss in women. Obesity (Silver Spring) 2014; 22: E13-E20.
117. Miras AD, le Roux CW,. Bariatric surgery and taste: novel mechanisms of weight loss. Curr Opin Gastroenterol 2010; 26: 140-145.
118. Jespersen MJ, Knop FK, Christensen M,. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013; 9: 17-29.
119. Buse JB, Garber A, Rosenstock J, et al., Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials. J Clin Endocrinol Metab 2011; 96: 1695-1702.
120. Unger JR, Parkin CG,. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabet Ther Res Treat Educ Diabet Related Disord 2011; 2: 29-39.
121. Shaffer EA,. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005; 7: 132-140.
122. Sadr-Azodi O, Orsini N, Andren-Sandberg A, Wolk A,. Abdominal and total adiposity and the risk of acute pancreatitis: a population-based prospective cohort study. Am J Gastroenterol 2013; 108: 133-139.
123. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E,. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabet Res Clin Pract 2014; 103: 269-275.
124. Noel RA, Braun DK, Patterson RE, Bloomgren GL,. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabet Care 2009; 32: 834-838.
125. Egan AG, Blind E, Dunder K, et al., Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.